



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Drewe *et al.*

Patent No.: 6,861,419
(from Appl. No. 09/836,548; Filed: April
18, 2001)

Issued: March 1, 2005

For: **Substituted 1, 4-Thiazepine and
Analogues as Activators of
Caspases and Inducers of
Apoptosis and the Use Thereof**

Confirmation No.: 6789

Art Unit: 1624

Examiner: Coleman, Brenda Libby

Atty. Docket: 1735.0450001/RWE/RAS

Request For Certificate Of Correction
Under 37 C.F.R. § 1.322

The Honorable Director of
Patents and Trademarks
Washington, DC 20231

Box: COC

Sir:

It is hereby requested that a Certificate of Correction under 37 C.F.R. § 1.322 be issued for the above-captioned United States Patent. This Certificate of Correction is being requested due to mistakes which appear in the printed patent. These mistakes were made by Applicant. The mistakes are of a clerical or typographical nature, or of a minor character. Patentees submit that correction of these errors does not introduce new matter.

Specifically, the printed patent contains the following errors for which a Certificate of Correction is respectfully requested:

04/12/2005 MBIZUNES 00000064 6861419

01 FC:1811

100.00 OP

Requested Change	Location of Support in File History	Error
On the face page, section (73), Assignee, after "(US)", please insert --; Axys Pharmaceuticals, Inc. , South San Francisco, CA (US)--.	Assignment to Axys Pharmaceuticals, Inc., by inventors E.J. Shelton, J. Litvak, D. Sperandio and J.R. Spencer, filed on July 2, 2001; and Assignment to Axys Pharmaceuticals, Inc., by inventor M. Sendzik, filed electronically on March 22, 2005.	Applicant

Remarks

The above-noted corrections do not involve such changes in the patent as would constitute new matter or would require reexamination.

A completed Form PTO-1050 accompanies this request, with the above-noted corrections printed thereon. Accordingly, a Certificate of Correction is believed proper and issuance thereof is respectfully requested.

This request is accompanied by payment of the fee set forth in 37 C.F.R. §1.20(a). Fee payment is provided in the attached Credit Card Payment Form (PTO-2038). The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert A. Schwartzman, Ph.D.
Agent for Applicants
Registration No. 50,211

Date: April 11, 2005

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
380773_1.DOC